Skip to main content
Fig. 2 | Lipids in Health and Disease

Fig. 2

From: Effect of intensive insulin treatment on plasma levels of lipoprotein-associated phospholipase A2 and secretory phospholipase A2 in patients with newly diagnosed type 2 diabetes

Fig. 2

Comparison of the Lp-PLA2 and sPLA2 levels between diabetic patients with macroangiopathy and those without macroangiopathy (133.43 [111.54, 145.17] ng/mL vs. 99.11 [63.02, 130.85] ng/mL, 235.73 [180.48, 416.46] ng/mL vs. 182.97 [90.08, 280.79] ng/mL, respectively) (a); changes of the Lp-PLA2 and sPLA2 levels after continuous subcutaneous insulin infusion (CSII) in all newly diagnosed type 2 diabetes (102.98 [76.34, 134.31] ng/mL vs. 88.35 [76.74, 125.18] ng/mL, 219.33 [130.03, 337.30] ng/mL vs. 173.78 [80.95, 278.09] ng/mL, respectively, n = 90) (b); changes of the Lp-PLA2 and sPLA2 levels after CSII in diabetic patients with or without macroangiopathy (Lp-PLA2: 133.43 [111.54, 145.17] ng/mL vs 92.16 [80.26, 128.78] ng/mL, P <0.05; 99.11 [63.02, 130.85] ng/mL vs. 85.94 [60.53, 119.76] ng/mL, P =0.102; sPLA2: 235.73 [180.48, 416.46] ng/mL vs. 183.76 [93.88, 271.54] ng/mL, P < 0.01; 182.97 [90.08, 280.79] ng/mL vs. 147.88 [76.58, 265.66] ng/mL, P < 0.05) (c). *P < 0.05, ** P < 0.01. Values of P < 0.05 are statistically significant

Back to article page

Lipids in Health and Disease

ISSN: 1476-511X